ResMed Inc.(RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest News & Analysis
ResMed's NightOwl: Transforming Sleep Apnea Diagnostics and RMD Stock
ResMed (RMD) is innovating sleep apnea diagnostics with NightOwl, an at-home test. Financial analysis reveals strong fundamentals. Upcoming Q3 2025 earnings are eagerly anticipated.
ResMed (RMD): AI, Brand Unification, and CPAP Therapy
ResMed is revolutionizing sleep apnea treatment with AI and brand unification. A Lancet study confirms CPAP therapy's life-saving benefits, boosting ResMed's market position.
ResMed (RMD): CPAP Study, Brand Unification, and AI Innovation – A Financial News Analysis
ResMed (RMD) advances with CPAP study validation, brand unification, and AI innovation. Financial analysis of recent developments and strategic moves.
ResMed (RMD): CPAP Therapy, AI Innovation, and Financial Outlook
ResMed (RMD) advances in sleep therapy, AI, and brand unification. Strong financials and a reliable dividend make RMD a compelling investment in the growing sleep apnea market.
ResMed (RMD): Brand Strategy, AI Investment, and Market Impact
Analysis of ResMed's brand unification, AI investments, and financial strategy. Examines market impact, debt management, and growth opportunities in sleep apnea.
ResMed's Unified Brand: Revolutionizing Sleep and Health Technology
ResMed's brand evolution unifies its portfolio, enhancing direct-to-consumer engagement. Strong financials, driven by AirSense and Philips recall, position RMD for growth.
ResMed Inc. Financial Update: Earnings, Growth & Strategic Developments
Deep-dive analysis of ResMed Inc. fundamentals, market performance, and strategic initiatives driving its future growth.
ResMed (RMD): Analyzing Growth, Market Impact, and Industry Trends
Analyzing ResMed's growth, market impact, and industry trends in sleep and respiratory care. An in-depth look at RMD's strategy and competitive landscape.
ResMed (RMD): Analyzing Growth Drivers, Market Trends, and Future Outlook
ResMed (RMD) demonstrates strong growth potential driven by robust Q2 FY25 results, increasing sleep apnea awareness, and strategic digital health initiatives.
ResMed: Strategy, Market Impact, and Industry Trends in 2025
ResMed's 2030 strategy, digital health initiatives, and market trends analyzed. Wearable tech, cloud solutions, and healthcare policy impacts assessed.
ResMed: Financial Performance, Market Strategy, and the Future of Sleep Apnea Treatment
ResMed's Q2 FY25 results show strong growth driven by AirSense 11 and efficient cost management. Wearable tech integration and strategic initiatives enhance long-term potential.
ResMed Navigates Market Shifts and Competitive Pressures in 2025
ResMed navigates a dynamic market with strong Q2 FY25 results, driven by AirSense 11 and cost management. Digital health is key, but GLP-1s pose a challenge.
ResMed’s Growth Trajectory: Navigating Market Trends and Innovation in Sleep Apnea Solutions
Explore ResMed’s Q2 2025 performance, innovative product portfolio, and strategic market trends driving growth in the sleep apnea solutions industry.
ResMed’s Strategic Growth: Market Expansion and Sleep Apnea Solutions
A comprehensive analysis of ResMed’s Q2 2025 performance, market trends, and strategic initiatives that drive growth.